Kymera Results Presentation Deck

● AN count of 0/1/2 response rate of 42 to 50% HISCR50 response rate of 42 to 50% HISCR75 response rate of 25 to 30% Pain NRS30 response in 50 to 60% and mean peak pruritis reduction of 62 to 68% Physician Global Assessment (PGA) scores improved in 5 of 12 patients, including 1 moderate disease patient with full disease clearance, and stable in the others KT-474 Part C Placebo Benchmarks Week 4 -15%¹ ΔΑΝ Count -46 to -51% AN Count 0/1/2 42 to 50% 24 to 26%3 28 to 47%2,3 HISCR50 42 to 50% 19 to 30% 3,4 5%4 29 to 51% 3,4 20%4 HISCR75 25 to 30% Pain NRS30 50 to 60% 18 to 23% 3,5 39 to 58%2,3,5 APeak Pruritus NRS -62 to -68% N/A N/A ¹Kimball AB, et al. Ann Intern Med 2012;157:846-55; 2Morita A, et al. J Dermatol 2021;48:3-13; ³Kimball AB, et al. NEJM 2016;375:422-434;4Glatt S et al. JAMA Dermatol 2021;157:1279-88; 5Scheinfeld, et al. Derm Online J 2016:22 The Adalimumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our KYMERA Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only ● ● ● KT-474 Showed Meaningful Signs of Clinical Activity in HS, Comparing Favorably to Placebo Benchmarks and SOC Summary Results ● Mean total AN count reduction of 46 to 51%, with maximum reduction up to 100% ©2022 KYMERA THERAPEUTICS, INC. Adalimumab Phase 2 and 3 Week 4 -31%¹ PAGE 59

View entire presentation